XML 53 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Agreements - Amgen (Details)
1 Months Ended 3 Months Ended 12 Months Ended 198 Months Ended
Feb. 29, 2016
item
Dec. 31, 2015
item
Sep. 30, 2015
USD ($)
Oct. 31, 2013
USD ($)
May 31, 2013
USD ($)
item
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2016
USD ($)
item
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Dec. 31, 2000
USD ($)
item
Jun. 30, 2016
USD ($)
Dec. 31, 2006
USD ($)
Collaborative Agreements disclosures                                      
Amount of arrangement consideration included in license and milestone fees           $ 76,000 $ 10,077,000 $ 10,692,000 $ 6,070,000 $ 5,086,000 $ 5,078,000 $ 41,417,000 $ 6,234,000 $ 26,915,000 $ 57,815,000 $ 39,455,000      
Costs related to the research and development services           38,652,000 $ 36,094,000 $ 38,199,000 $ 35,132,000 $ 30,437,000 $ 25,666,000 $ 27,647,000 $ 28,018,000 148,077,000 111,768,000 106,958,000      
Development and Commercialization License | Development milestones                                      
Collaborative Agreements disclosures                                      
Potential milestone payments                                     $ 4,500,000
Amgen                                      
Collaborative Agreements disclosures                                      
Costs related to the research and development services                           15,000 62,000 179,000      
Costs related to clinical materials sold                           $ 0 $ 0 664,000      
Amgen | Development and Commercialization License                                      
Collaborative Agreements disclosures                                      
Number of single-target licenses | item   4     1                 2     3    
Fee received per license       $ 500,000 $ 500,000                       $ 1,000,000    
Number of licenses terminated | item 2 2                                  
Potential milestone payments       $ 34,000,000                              
Estimated term of development and commercialization license       25 years                              
Discount rate (as a percent)       13.00%                              
Remaining arrangement consideration to be recognized as license revenue       $ 430,000                              
Amount of arrangement consideration included in license and milestone fees                               $ 2,200,000   $ 3,000,000  
Estimated utilization period after commercialization       10 years                              
Amgen | Development and Commercialization License | Development milestones                                      
Collaborative Agreements disclosures                                      
Potential milestone payments       $ 9,000,000                              
Amgen | Development and Commercialization License | IND application filed                                      
Collaborative Agreements disclosures                                      
Potential milestone payments           1,000,000               $ 1,000,000       1,000,000  
Amount of arrangement consideration included in license and milestone fees     $ 1,000,000                                
Amgen | Development and Commercialization License | Phase II clinical trial                                      
Collaborative Agreements disclosures                                      
Potential milestone payments           $ 3,000,000               $ 3,000,000       $ 3,000,000  
Amgen | Development and Commercialization License | Regulatory milestones                                      
Collaborative Agreements disclosures                                      
Potential milestone payments       20,000,000                              
Amgen | Development and Commercialization License | Sales milestones                                      
Collaborative Agreements disclosures                                      
Potential milestone payments       $ 5,000,000